What is an anti-angiogenic drug? How does it treat lung cancer? Anti-angiogenic drug is a kind of vascular targeting drug, which is different from traditional drugs for lung cancer treatment; the latter is often called chemotherapy drugs, which mainly fight against tumor cells and have strong cytotoxicity, and can kill some tumor cells initially. This phenomenon is called “partial remission”. It is best if we can maintain partial remission and maintain the state of human tumor coexistence, but it is often not the case: when chemotherapy is stopped, tumor cells will grow rapidly. It is found that the most important reason for rapid growth of tumor is the nutritional support of tumor cells, that is, many new blood vessels appear around the tumor cells, and these blood vessels are like “food logistics”, which makes tumor cells resurface. Anti-angiogenic drugs are drugs to combat the new blood vessels around the tumor and change the microenvironment of tumor growth, just like we fight against the enemy’s troops, if we do not cut off its supply of food and grass, it will resurface eventually. What is the difference between anti-angiogenic drugs and targeted drugs such as erlotinib and gefitinib? The point of action of drugs such as Erlotinib and Gefitinib is the tumor itself. The receptors of tumor cells are like keyholes, and targeted drugs are like a key to the tumor receptors and thus the treatment. The point of action of anti-angiogenic drugs is on the endothelial cells of the tumor vascular network, and it attacks the microenvironment of the tumor. What is the therapeutic effect of anti-angiogenic drugs? The role of anti-angiogenic drugs is to cut off the enemy’s food, and chemotherapeutic drugs are to combat the enemy’s legion. The latest clinical trials have shown that the combination is more effective than conventional chemotherapy alone, both in terms of short-term effects and in maintaining long-term tumor stability.